Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of ...
The study investigated the effects of quercetin and putative mechanisms involved against endosulfan-testicular impairments in rats. Rats were allotted into five treatment groups (n = 5). G...
The study investigated the effects of quercetin and putative mechanisms involved against endosulfan-testicular impairments in rats. Rats were allotted into five treatment groups (n = 5). G...
When three-dose schedule antibody concentrations are reached in patients with blood cancer who are immunocompromised, they are comparable to that of healthy controls after two doses. ...
For most patients with mantle cell lymphoma (MCL), programmed death 1 and its ligand (PD-1/PD-L1) inhibitors do not appear to be appropriate treatment options, according to Farid Kosari. ...
“New treatments for mantle cell lymphoma (MCL) have improved survival and increased the life expectancy of survivors,” says Ingrid Glimelius, MD, PhD. “However, due to patients with MC...
Click to read this study in the Journal of Clinical Oncology. ...
Early-stage pediatric classic Hodgkin lymphoma was treated with response-adapted involved-field radiotherapy (IFRT) instead of systemic treatment in the Children's Oncology Group (COG) study...
Data indicate that nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for approximately 5% of all Hodgkin lymphoma (HL) cases. The incidence is roug...
A recently developed diagnostic category for aggressive B-cell lymphomas is high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS). It contains tumors that lack double-hit cytogene...
With no indication of systemic involvement, primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous cancer that affects the brain, spinal cord, leptomeninges, or vi...
The treatment landscape in Hodgkin lymphoma (HL) has changed significantly in recent years with the FDA approval of 2 immune checkpoint blockade (ICB) therapies and more of these agents are ...
For recurrent or refractory large B-cell lymphoma (LBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is regarded as the standard of care (SOC) second-line...
We propose an efficient method to modify B-cell derived EVs by loading them with a nanotherapeutic stimuli-responsive cargo and equipping them with antibodies for efficient targeting of lymp...
Primary central nervous system lymphoma (PCNSL) is a form of extranodal non-Hodgkin's B-cell lymphoma limited to the CNS. The treatment of PCNSL is ineffective partly due to the blood-brain ...
High rates of relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients and life-threatening side effects associated with immunochemotherapy make an urgent need to develop new t...
Lymphomas, or cancers of the lymphatic system, account for around half of all blood cancers diagnosed each year. Lymphoma is a condition that is difficult to diagnose, and accurate diagnosis...
CD19-directed chimeric antigen receptor T cells (CAR T) are approved for treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following at least two lines of t...
Cytogenetic studies have played a crucial role in the discovery of genes involved in several diseases. In the field of oncohematology, cytogenetics is still necessary for the classification ...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
